Impact of BRICS’ investment in vaccine development on the global vaccine market

Kaddar, Miloud; Milstien, Julie B.; Schmitt, Sarah

doi:10.2471/blt.13.133298

Cited by 28 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the turn of the 21 st century, EPI expanded the range of VPD by introducing new vaccines in LMIC (102). An increasing number of vaccine products are now available, some developed primarily for use in LMIC and several available from manufacturers (103). …”

Section: Monitoring Vaccine Safety In Low- and Middle-income Countmentioning

confidence: 99%

Enhancing vaccine safety capacity globally: A lifecycle perspective

Chen

Shimabukuro

Martín

et al. 2015

Vaccine

View full text Add to dashboard Cite

Major vaccine safety controversies have arisen in several countries beginning in the last decades of 20th Century. Such periodic vaccine safety controversies are unlikely to go away in the near future as more national immunization programs mature with near elimination of target vaccine-preventable diseases that result in relative greater prominence of adverse events following immunizations, both true reactions and temporally coincidental events. There are several ways in which vaccine safety capacity can be improved in the future to potentially mitigate the impact of future vaccine safety controversies. This paper aims to take a “lifecycle” approach, examining some potential pre- and post-licensure opportunities to improve vaccine safety, in both developed (specifically U.S. and Europe) and low- and middle- income countries.

show abstract

Section: Monitoring Vaccine Safety In Low- and Middle-income Countmentioning

confidence: 99%

Enhancing vaccine safety capacity globally: A lifecycle perspective

Chen

Shimabukuro

Martín

et al. 2015

Vaccine

View full text Add to dashboard Cite

show abstract

“…Apparently, the goal was to build health systems with broad coverage 11 in order to ensure better health and to maintain a prominent role in building a global health agenda 12 . Studies have sought to understand the possibilities of joint cooperation between these countries in fields such as the production of drugs and vaccines, in the fight against tuberculosis, as well as in the treatment of HIV/AIDS and historically neglected diseases [13][14][15][16][17] .…”

Section: Introductionmentioning

confidence: 99%

Diferenças e desigualdades no acesso a terapia renal substitutiva nos países do BRICS

Ferraz

Rodrigues

Gatto

et al. 2017

Ciênc. saúde coletiva

View full text Add to dashboard Cite

End-stage renal disease (ESRD) is an important public health problem, especially in developing countries due to the high level of economic resources needed to maintain patients in the different programs that make up renal replacement therapy (RRT). To analyze the differences and inequalities involved in access to RRT in the BRICS countries (Brazil, Russian Federation, India, China and South Africa). This is an applied, descriptive, cross-sectional, quantitative and qualitative study, with documentary analysis and a literature review. The sources of data were from national censuses and scientific publications regarding access to RRT in the BRICS countries. There is unequal access to RRT in all the BRICS countries, as well as the absence of information regarding dialysis and transplants (India), the absence of effective legislation to inhibit the trafficking of organs (India and South Africa) and the use of deceased prisoners as donors for renal transplants (China). The construction of mechanisms to promote the sharing of benefits and solidarity in the field of international cooperation in the area of renal health involves the recognition of bioethical issues related to access to RRT in the BRICS countries.

show abstract

“…In a systematic literature review, Andrew Harmer and colleagues (2013, 1) noted an 'overwhelming tendency to describe individual BRICS countries [sic] influence' (see also Ezziane 2014). Much of the literature has concentrated on country-specific analyses (Lancet 2009(Lancet , 2011a(Lancet , 2011b(Lancet , 2012(Lancet , 2013, investigations of shared health challenges (Creswell et al 2014;Cashwell et al 2014;Ernest et al 2014;Marten et al 2014;Rao et al 2014), or opportunities for technological developments (Ezziane 2014;Kaddar, Milstien, and Schmitt 2014). Several researchers have examined BRICS health initiatives vis-à-vis global health (Fleck and Harmer 2014;Watt, Gomez, and McKee 2014;Buss, Ferreira, and Hoirisch 2014), in large part asking: 'to what extent does it make sense to talk of "the BRICS" as a coherent unit of analysis?'…”

Section: Introductionmentioning

confidence: 99%

BRICS health and tuberculosis control collaborations during an era of global health

Dirlikov¹

2015

MAT

View full text Add to dashboard Cite

In this think piece, I examine the difference introduced by BRICS (Brazil, Russia, India, China, and South Africa) health collaborations in an era of global health. Using tuberculosis control as a grounding example, I show that BRICS collaborations prioritize: state-led solutions, particularly through policies aimed at expanding universal health coverage; scientific and programmatic innovation; experience and technology sharing; clear benchmarks for progress, based on current best practices of control; and flexibility. Unlike international health, BRICS health collaborations are not primarily concerned with preventing the importation of infectious disease across national borders. Nor are they based on global health's concerns about global biosecurity or humanitarian biomedicine. Rather, BRICS collaborative health efforts fall within the nation-state paradigm, while also aspiring towards the global. They remain flexible in their operation, gesturing towards a neoliberal ethic. This flexibility allows BRICS to work within existing structures, while also establishing their own institutions from which to change traditional assistance relationships.

show abstract

Impact of BRICS’ investment in vaccine development on the global vaccine market

Cited by 28 publications

References 9 publications

Enhancing vaccine safety capacity globally: A lifecycle perspective

Enhancing vaccine safety capacity globally: A lifecycle perspective

Diferenças e desigualdades no acesso a terapia renal substitutiva nos países do BRICS

BRICS health and tuberculosis control collaborations during an era of global health

Contact Info

Product

Resources

About